A growing body of genetic and epidemiological research now points to the same conclusion: there is no clearly safe level of alcohol consumption when it comes to cancer, cardiovascular disease, and premature death. A 2024 Mendelian randomization study found increased odds of all-cause, cardiovascular, and cancer mortality with each unit increase in alcohol intake, challenging decades of observational research that suggested a glass of wine a day might protect the heart. The International Agency for Research on Cancer has long classified alcoholic beverages as a Group 1 carcinogen, and a 2020 global burden analysis estimated that even light-to-moderate consumption accounts for a meaningful share of new cancer cases worldwide.
Why the “no safe level” finding changes the debate
For years, public health guidelines in the United States and Europe allowed room for moderate drinking, typically defined as up to one drink per day for women and two for men. That guidance rested largely on observational studies comparing drinkers to non-drinkers. The problem, researchers have argued, is that those studies suffered from a well-known bias: many people classified as “non-drinkers” had actually quit because of illness, making moderate drinkers look healthier by comparison.
The 2024 study published in the International Journal of Epidemiology used Mendelian randomization, a technique that relies on genetic variants associated with alcohol metabolism to simulate a natural experiment. Because genes are assigned at conception, they are not tangled up with the lifestyle and health factors that confuse traditional studies. The results showed higher odds of dying from any cause, from cardiovascular disease, and from cancer as alcohol intake rose, with no protective threshold at low doses.
That genetic evidence arrives alongside a separate question now facing regulators: whether alcohol containers should carry gram-based cancer risk labels, similar to the calorie counts on food packaging. Countries or states that adopt such labeling could see faster reductions in drinking among adults aged 35 to 54, the demographic most likely to be consuming at “moderate” levels and most exposed to cumulative cancer risk. Jurisdictions that rely only on vague “drink responsibly” messaging lack the specificity to change behavior at the point of purchase. Whether labeling alone can shift intake faster than general health campaigns is an open question, but the logic tracks with evidence from tobacco: concrete, quantified warnings outperform abstract ones.
Genetic studies and global cancer data converge
The case against moderate drinking draws strength from several independent lines of evidence. The IARC classified alcohol as a Group 1 carcinogen based on sufficient evidence linking it to cancers of the mouth, pharynx, larynx, esophagus, liver, colorectum, and female breast. Group 1 is the agency’s highest designation, shared with tobacco smoking and asbestos.
A population-based study published in The Lancet Oncology estimated the global burden of cancer attributable to alcohol in 2020, broken down by cancer site, sex, and exposure level. That analysis found that light-to-moderate consumption, defined as fewer than 20 grams of ethanol per day, still contributed a non-trivial share of new alcohol-attributable cancer cases worldwide. In the United States, a standard drink contains roughly 14 grams of ethanol, according to the National Institute on Alcohol Abuse and Alcoholism. That means a person drinking just one standard drink per day already falls within the exposure range the study flagged.
Additional guidance from the U.S. National Cancer Institute notes that alcohol increases the risk of several malignancies and emphasizes that risk rises with dose, with no clear threshold below which drinking is entirely without concern; its alcohol and cancer overview highlights consistent links to cancers of the breast, liver, colon, head, and neck. Taken together, the global burden estimates, IARC classifications, and national cancer guidance converge on a stark message: even low levels of regular intake can contribute to disease.
A separate European analysis focused specifically on cancers caused by light-to-moderate intake across the European Union, isolating drinkers who consumed fewer than 20 grams per day. The results reinforced the global findings: even at consumption levels many people consider harmless, alcohol contributed to a measurable number of incident cancer cases. The IARC, in a press release accompanying the Lancet Oncology study, stated that light-to-moderate drinking accounts for a non-trivial fraction of alcohol-attributable cancers, a line that health agencies have since cited when arguing there is no safe threshold.
Gaps in the data and what drinkers should watch
Several important questions remain unresolved. No publicly available U.S. vital-statistics linkage currently maps state-level cancer or mortality rates by exact grams-per-day intake, which means researchers cannot yet say precisely how many American deaths each year trace to one-drink-a-day habits versus heavier consumption. The 2024 Mendelian randomization study has not yet prompted the National Institute on Alcohol Abuse and Alcoholism or the Centers for Disease Control and Prevention to formally update the 2020–2025 Dietary Guidelines for Americans with new low-risk thresholds based on genetic evidence. And the raw cohort-level genotype and consumption data behind the Mendelian randomization findings have not been released for independent verification, a standard step that would strengthen confidence in the results.
There are also open questions about how risk varies by pattern of use. Most large studies focus on average grams per day, but many people drink intermittently, consuming several drinks on weekends and little to none during the week. From a biological standpoint, peak blood alcohol levels, repeated tissue exposure to acetaldehyde (a toxic metabolite of ethanol), and interactions with other carcinogens such as tobacco smoke likely all matter. Yet the fine-grained data needed to separate the risks of a steady daily drink from those of occasional binges remain sparse.
Still, the direction of the evidence is consistent. The old assumption that a daily glass of red wine protects the heart has been weakened by genetic research designed to strip out the biases that propped up that claim. Cancer risk from alcohol is dose-dependent, meaning it rises with each additional drink, and the same appears true for overall mortality. While some earlier observational studies suggested a J-shaped curve-where light drinkers seemed to fare better than abstainers-Mendelian randomization and careful re-analyses that exclude former drinkers from the “non-drinker” group have largely erased that apparent benefit.
For individuals who currently drink at what guidelines have called moderate levels, several practical steps follow from this emerging science. First, it is reasonable to revisit what “moderate” means personally, recognizing that one daily drink over decades is not risk-free, particularly for cancers of the breast and digestive tract. Second, people with a strong family history of these cancers, or with other risk factors such as smoking or obesity, may wish to cut back further or abstain, since risks from different exposures can compound.
Third, small reductions in intake can still matter. Because risk increases with dose, trimming from a daily drink to a few drinks per week, or from multiple drinks per occasion to just one, is likely to move risk in the right direction even if it does not eliminate it. Public health agencies increasingly emphasize that “less is better” rather than promising a sharp cutoff between safe and unsafe use.
Finally, the policy debate over labeling, marketing, and availability is likely to intensify as genetic and global burden data accumulate. Clear, gram-based labels that spell out cancer risk per unit of alcohol would bring beverages closer to the transparency standard already applied to food and tobacco. Whether those labels appear on bottles, menus, or retail websites, they could help align everyday decisions with what the science now suggests: when it comes to long-term health, the safest level of drinking is lower than many people have been led to believe-and for some, it may be no drinking at all.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
